Skip to main
HOTH
HOTH logo

Hoth Therapeutics (HOTH) Stock Forecast & Price Target

Hoth Therapeutics (HOTH) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Hoth Therapeutics Inc is advancing its clinical pipeline with a disciplined approach to expense management, demonstrating a strategic commitment to develop therapies for unmet medical needs, including oncology and neuroinflammatory diseases. The positive impact of their joint venture programs and progress in IND-enabling work is anticipated to create incremental value, further solidifying Hoth's dual-track strategy. Additionally, promising clinical trial results indicate that over 65% of participants experienced reductions in pain and pruritus, suggesting strong potential for therapeutic efficacy and overall symptom improvement.

Bears say

Hoth Therapeutics Inc reported a significant net loss of approximately $4.11 million for the quarter, translating to a loss of $(0.30) per share, which highlights ongoing financial challenges. The company recorded no revenues during the quarter, continuing a trend that underscores the absence of product commercialization or market entry. Additionally, although total operating expenses decreased from $3.4 million to $2.2 million compared to the previous quarter, the persistent lack of revenue raises concerns about the financial sustainability of Hoth Therapeutics's operations and future growth potential.

Hoth Therapeutics (HOTH) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hoth Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hoth Therapeutics (HOTH) Forecast

Analysts have given Hoth Therapeutics (HOTH) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Hoth Therapeutics (HOTH) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hoth Therapeutics (HOTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.